1. University of Southern California (5 from 1,630 patents)

2. Ab Science (5 from 28 patents)

3. Janssen Pharmaceutica Nv (4 from 2,078 patents)

4. Centre National De La Recherche Scientifique (2 from 5,081 patents)

5. Merck Sharp + Dohme Corp. (2 from 2,405 patents)

6. Institut Curie (2 from 154 patents)

7. Vetoquinol S.a. (2 from 9 patents)

8. Eli Lilly and Company (1 from 4,446 patents)

9. F. Hoffmann-la Roche Ag (1 from 168 patents)

10. European Molecular Biology Laboratory (1 from 64 patents)

11. Bionomics Inc. (1 from 64 patents)

12. Savira Pharmaceuticals Gmbh (1 from 8 patents)

13. Prestwick Chemical, Inc. (1 from 1 patent)

14. Eli Lilly (1 from 1 patent)

15. Domain Therapeutics (4 patents)

1. 10889563 - Deoxyuridine triphosphatase inhibitors

2. 10457673 - Heteroatom containing deoxyuridine triphosphatase inhibitors

3. 10227326 - Deoxyuridine triphosphatase inhibitors

4. 9994518 - Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof

5. 9809571 - Deoxyuridine triphosphatase inhibitors

6. 9790173 - Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I

7. 9790214 - Heteroatom containing deoxyuridine triphosphatase inhibitors

8. 9434745 - 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease

9. 9062013 - Positive allosteric modulators of the α7 nicotinic acetylcholine receptor and uses thereof

10. 8993573 - 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors

11. 8962627 - Oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors

12. 8835435 - 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors

13. 8450302 - 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors

14. 8404683 - Inhibitors of the interaction between MDM2 and P53

15. 8377961 - Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and P53